Funding Details
- Date Award
- May 13, 2024
- Vertical
- Human Health
- Funding URL
- View Funding Page
Company Info
- Organizations Involved
- None
- Founders
- Andrew Gray, Joseph Turner, Alan Johnson
- Company Description
- Karma is an in vivo cell therapy company that uses a proprietary LNP technology to reprogram key immune cells to infiltrate tumors and break down their defenses from within. Karma’s ionizable LNPs can target and reprogram macrophages within the spleen using DNA, RNA, or both, which can then home to tumor sites and produce therapeutics directly within the tumor microenvironment. Karma’s technology is initially focused on cytokines and other biologicals, such as IL-15, locally within tumors and metastatic sites. Localized IL-15 production can turn cold tumors hot, potentiating immunotherapies while avoiding the dangers of systemic toxicity. Karma will advance through their own internal drug program while also partnering in parallel. The company already has an active paid partnership with a public pharma company and is in post-LOI discussions around another paid partnership early next year.
- Market
- Therapeutics
- Location
-
United States
Links